ROS1 and non-small cell lung carcinoma: Among the clinically predictive biomarkers recommended for testing as per the NCCN clinical guidelines version 2.2023 in NSCLC, no alterations or rearrangements were detected in NTRK1, NTRK2, or ROS1 in these samples.